19.69

2.55% 0.49

Adma Biologics Inc (ADMA)

Overview News Price History Option Chain Financials Discussions Forecast

Adma Biologics Inc stock is traded at $19.69, with a volume of 2.52M. It is up +2.55% in the last 24 hours and down -7.25% over the past month. ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Previous Close:

$19.20

Open:

$19.26

24h Volume:

2.52M

Relative Volume:

0.73

Market Cap:

$4.70B

Revenue:

$426.45M

Net Income/Loss:

$197.67M

P/E Ratio:

24.01

EPS:

0.82

Net Cash Flow:

$110.10M

1W Performance:

-1.45%

1M Performance:

-7.25%

6M Performance:

+3.41%

1Y Performance:

+117.33%

1-Day Range:

$19.23

$19.97

1-Week Range:

$18.95

$20.82

52-Week Range:

$8.91

$25.67

Adma Biologics Inc Stock (ADMA) Company Profile

Name

Adma Biologics Inc

Sector

Healthcare (1170)

Industry

Biotechnology (671)

Phone

(201) 478-5552

Address

C/O ADMA BIOLOGICS, INC., RAMSEY

Employee

685

Twitter

@AdmaBiologics

Next Earnings Date

2025-03-03

Latest SEC Filings

ADMA's Discussions on Twitter

Compare ADMA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADMA Adma Biologics Inc	19.69	4.77B	426.45M	197.67M	110.10M	0.82
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-19-23	Resumed	Raymond James	Strong Buy
Oct-13-22	Initiated	Mizuho	Buy
Nov-11-21	Upgrade	Raymond James	Outperform → Strong Buy
Nov-09-21	Initiated	Cantor Fitzgerald	Overweight
Jun-04-19	Initiated	Jefferies	Buy
Apr-15-19	Reiterated	H.C. Wainwright	Buy
Feb-07-19	Resumed	H.C. Wainwright	Buy
Dec-11-17	Reiterated	Maxim Group	Buy
Nov-14-17	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-23-17	Upgrade	Maxim Group	Hold → Buy
Aug-01-16	Downgrade	Maxim Group	Buy → Hold
Jul-25-16	Reiterated	Maxim Group	Buy
May-13-15	Reiterated	Maxim Group	Buy
Dec-08-14	Initiated	Oppenheimer	Outperform
Dec-01-14	Reiterated	Maxim Group	Buy

View All

Adma Biologics Inc Stock (ADMA) Latest News

May 16, 2025

ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss (NASDAQ:ADMA) - Seeking Alpha

May 09, 2025

ADMA Biologics Reports Strong Growth and Strategic Advances - TipRanks

May 09, 2025

May 08, 2025

ADMA Biologics (ADMA) Receives Price Target Upgrade from Raymond James | ADMA Stock News - GuruFocus

May 08, 2025

ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock? - Yahoo Finance

May 08, 2025

Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits - MSN

May 08, 2025

Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga

May 08, 2025

Adma Biologics price target raised to $32 from $25 at Raymond James - TipRanks

May 08, 2025

Raymond James Increases Price Target for ADMA Biologics | ADMA Stock News - GuruFocus

May 08, 2025

ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2025 Earnings Call Transcript - Insider Monkey

May 08, 2025